WHO/Daniel Hodgson
© Credits



    Measles is a highly contagious viral disease. It remains an important cause of death among young children globally, despite the availability of a safe and effective vaccine.

    While vaccination has drastically reduced global measles deaths — a 73% drop between 2000-2018 worldwide — measles is still common in many developing countries, particularly in parts of Africa and Asia. More than 140,000 people died from measles in 2018. The overwhelming majority (more than 95%) of measles deaths occur in countries with low per capita incomes and weak health infrastructures.

    Member States in all WHO Regions have adopted measles elimination goals. WHO is the lead technical agency responsible for coordination of immunization and surveillance activities supporting all countries to achieve these goals.


    Measles is transmitted via droplets from the nose, mouth or throat of infected persons. Initial symptoms, which usually appear 10–12 days after infection, include high fever, a runny nose, bloodshot eyes, and tiny white spots on the inside of the mouth. Several days later, a rash develops, starting on the face and upper neck and gradually spreading downwards.

    Severe measles is more likely among poorly nourished young children, especially those with insufficient vitamin A, or whose immune systems have been weakened by HIV/AIDS or other diseases. The most serious complications include blindness, encephalitis (an infection that causes brain swelling), severe diarrhoea and related dehydration, and severe respiratory infections such as pneumonia.


    Routine measles vaccination for children, combined with mass immunization campaigns in countries with low routine coverage, are key public health strategies to reduce global measles deaths.

    The measles vaccine has been in use since the 1960s. It is safe, effective and inexpensive. WHO recommends immunization for all susceptible children and adults for whom measles vaccination is not contraindicated. Reaching all children with 2 doses of measles vaccine, either alone, or in a measles-rubella (MR), measles-mumps-rubella (MMR), or measles-mumps-rubella-varicella (MMRV) combination, should be the standard for all national immunization programmes.

    Latest publications

    All →
    Ninth South-East Asia Regional Meeting of Virologists of the Measles and Rubella Laboratory Network, Lucknow, India, 1–2 September 2022

    The Global Measles and Rubella Laboratory Network (GMRLN) is the largest internationally coordinated laboratory network providing high-quality laboratory...

    Meeting of the Immunization and Vaccine-related Implementation Research Advisory Committee (IVIR-AC), September 2022

    The IVIR-AC recommendations are based on technical discussions during a hybrid (in-person/virtual) meeting of the IVIR-AC, held on 12–14 September...

    Measles Outbreak Guide

    The conclusions of the Global Measles and Rubella Strategic Plan 2012–2020 implementation midterm review highlighted the need to update protocols...

    Measles outbreaks strategic response plan: 2021–2023:

    The Measles Outbreaks Strategic Response Plan 2021–2023 (MOSRP) supports the achievement of the strategic priorities of the post-2020 Measles and...